Coeptis Therapeutics (NASDAQ:ZSQR) Trading 10% Higher – Still a Buy?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) rose 10% during trading on Friday . The company traded as high as $9.16 and last traded at $8.98. Approximately 228,731 shares traded hands during trading, an increase of 28% from the average daily volume of 179,290 shares. The stock had previously closed at $8.16.

Coeptis Therapeutics Price Performance

The company has a 50 day moving average price of $12.21 and a 200-day moving average price of $13.48. The company has a market cap of $55.88 million, a price-to-earnings ratio of -3.56 and a beta of -0.09. The company has a quick ratio of 4.16, a current ratio of 3.25 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The business had revenue of $0.11 million for the quarter.

Institutional Trading of Coeptis Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in Coeptis Therapeutics during the 4th quarter worth $259,000. Yorkville Advisors Global LP bought a new stake in shares of Coeptis Therapeutics in the 3rd quarter valued at about $140,000. State Street Corp increased its stake in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares during the period. Geode Capital Management LLC increased its stake in shares of Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the last quarter. 13.88% of the stock is currently owned by institutional investors and hedge funds.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.